Document Detail


Role of biomarkers in chemotherapy-induced cardiotoxicity.
MedLine Citation:
PMID:  20728699     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chemotherapy-induced cardiotoxicity remains an unresolved problem strongly impacting the quality of life and the overall survival of cancer patients. The main strategy for minimizing cardiotoxicity is early detection of high-risk patients and prompt prophylactic treatment. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategies. Measurement of cardiospecific biomarkers can be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. In particular, the role of troponin in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing cardiac dysfunction and cardiac events is clearly emerging as a new effective approach. Therefore, we propose troponin as a criterion standard marker for the assessment of cardiac risk of both old and new antineoplastic treatments, and its evaluation should be included among the criteria utilized to define cardiotoxicity.
Authors:
Daniela Cardinale; Maria Teresa Sandri
Related Documents :
7994859 - Survival and predictors of survival in patients with congestive heart failure due to ch...
2046709 - Predictors of event-free survival after balloon aortic valvuloplasty.
9680019 - Prehospital pulseless, unconscious penetrating trauma victims: field assessments associ...
320159 - Probability of survival in hypertensive and nonhypertensive patients on maintenance hem...
15754279 - Dialyzer membrane permeability and survival in hemodialysis patients.
11975839 - Cardiac amyloidosis: a case report and therapeutic implications.
12496859 - Maximum androgen-blockade with medical or surgical castration in advanced prostate canc...
18084249 - The prognostic value of histological grading of posterior fossa ependymomas in children...
20425409 - Prognostic factors in low-grade non-hodgkin lymphomas.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  53     ISSN:  1873-1740     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-08-23     Completed Date:  2010-09-27     Revised Date:  2013-05-02    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  121-9     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy. daniela.cardinale@ieo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects*
Biological Markers / blood
Early Diagnosis
Heart Diseases / blood,  chemically induced,  diagnosis*,  prevention & control
Humans
Natriuretic Peptides / blood
Neoplasms / drug therapy*
Predictive Value of Tests
Risk Assessment
Troponin / blood*
Up-Regulation
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Biological Markers; 0/Natriuretic Peptides; 0/Troponin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
Next Document:  Management of trastuzumab-related cardiac dysfunction.